The ASSIST Study - The BD Odon Device for assisted vaginal birth: a safety and feasibility study.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
05 Mar 2019
Historique:
received: 27 11 2018
accepted: 16 02 2019
entrez: 7 3 2019
pubmed: 7 3 2019
medline: 18 7 2019
Statut: epublish

Résumé

Assisted vaginal birth is a vital health intervention that can result in better outcomes for mothers and their babies when complications arise in the second stage of labour. Unfortunately, instruments for assisted vaginal birth (forceps and ventouse) are often not utilised in settings where there is most clinical need, resulting in maternal and neonatal morbidity and mortality which could have been prevented. The BD Odon Device is a new device for assisted vaginal birth that may be able to address this unmet need. However, before dissemination, the device requires evaluation in robust clinical trials. A feasibility study to investigate the clinical impact, safety, and acceptability of the BD Odon Device for assisted vaginal birth is therefore planned. This will provide further information on acceptability, recruitment, and the outcome data required to design a future randomised controlled trial of the BD Odon Device versus Kiwi ventouse. Forty women who require an assisted vaginal birth for a recognised clinical indication will have the birth assisted with the BD Odon Device. The primary outcome is successful vaginal birth completed with the BD Odon Device. Secondary clinical outcomes include maternal and neonatal outcomes, and maternal and practitioner satisfaction. Safety data will be reviewed following every birth. A future randomised controlled trial of the BD Odon Device versus the current standard instrument (the Kiwi ventouse) is planned. The findings of the ASSIST Study will inform the randomised controlled trial design. ISRCTN, ISRCTN10203171 . Prospectively registered on 27 July 2018.

Sections du résumé

BACKGROUND BACKGROUND
Assisted vaginal birth is a vital health intervention that can result in better outcomes for mothers and their babies when complications arise in the second stage of labour. Unfortunately, instruments for assisted vaginal birth (forceps and ventouse) are often not utilised in settings where there is most clinical need, resulting in maternal and neonatal morbidity and mortality which could have been prevented. The BD Odon Device is a new device for assisted vaginal birth that may be able to address this unmet need. However, before dissemination, the device requires evaluation in robust clinical trials. A feasibility study to investigate the clinical impact, safety, and acceptability of the BD Odon Device for assisted vaginal birth is therefore planned. This will provide further information on acceptability, recruitment, and the outcome data required to design a future randomised controlled trial of the BD Odon Device versus Kiwi ventouse.
METHODS METHODS
Forty women who require an assisted vaginal birth for a recognised clinical indication will have the birth assisted with the BD Odon Device. The primary outcome is successful vaginal birth completed with the BD Odon Device. Secondary clinical outcomes include maternal and neonatal outcomes, and maternal and practitioner satisfaction. Safety data will be reviewed following every birth.
DISCUSSION CONCLUSIONS
A future randomised controlled trial of the BD Odon Device versus the current standard instrument (the Kiwi ventouse) is planned. The findings of the ASSIST Study will inform the randomised controlled trial design.
TRIAL REGISTRATION BACKGROUND
ISRCTN, ISRCTN10203171 . Prospectively registered on 27 July 2018.

Identifiants

pubmed: 30836979
doi: 10.1186/s13063-019-3249-z
pii: 10.1186/s13063-019-3249-z
pmc: PMC6402154
doi:

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

159

Subventions

Organisme : Medical Research Council
ID : MR/K025643/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/S001751/1
Pays : United Kingdom
Organisme : Bill & Melinda Gates Foundation
ID : OPP1184825
Pays : United States

Investigateurs

Mary Alvarez (M)
Sabaratnum Arulkumaran (S)
Nichola Bale (N)
Natalie Blencowe (N)
Joanna F Crofts (JF)
Timothy J Draycott (TJ)
Lily Exell (L)
Anne Glover (A)
Sally Hall (S)
Emily J Hotton (EJ)
Erik Lenguerrand (E)
Helen Lewis-White (H)
Naomi Mallinson (N)
Michelle Mayer (M)
Sadie McKeown-Keegan (S)
Glen Mola (G)
Stephen O'Brien (S)
Alison Pike (A)
Iona Smith (I)
Claire Rose (C)
Sherrie Villis (S)
Julia Wade (J)
Paul White (P)
Cathy Winter (C)

Références

BMC Med. 2010 Nov 10;8:71
pubmed: 21067593
BJOG. 2017 Sep;124 Suppl 4:26-34
pubmed: 28940870
BJOG. 2017 Sep;124 Suppl 4:35-43
pubmed: 28940874
BJOG. 2016 Mar;123(4):559-68
pubmed: 25753683
Lancet. 2015 Jan 10;385(9963):117-71
pubmed: 25530442
Int J Gynaecol Obstet. 2006 Aug;94(2):185-9
pubmed: 16828772
BJOG. 2017 Aug;124(9):1335-1344
pubmed: 28139878
Natl Vital Stat Rep. 2015 Jan 15;64(1):1-65
pubmed: 25603115
BJOG. 2017 Sep;124 Suppl 4:10-18
pubmed: 28940873
BJOG. 2005 Nov;112(11):1510-5
pubmed: 16225571
BMC Pregnancy Childbirth. 2016 Sep 02;16:258
pubmed: 27590680
BJOG. 2017 Sep;124 Suppl 4:5-6
pubmed: 28940871
BJOG. 2017 Sep;124 Suppl 4:19-25
pubmed: 28940875
Lancet. 2001 Oct 13;358(9289):1203-7
pubmed: 11675055
Reprod Health. 2018 Mar 12;15(1):45
pubmed: 29526165
Lancet. 2006 Apr 1;367(9516):1066-1074
pubmed: 16581405
Acta Obstet Gynecol Scand Suppl. 1954;33(4):1-31
pubmed: 13196986
BMJ Glob Health. 2016 Jul 7;1(1):e000020
pubmed: 28588915

Auteurs

Stephen O'Brien (S)

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Women & Children's Directorate, North Bristol NHS Trust, Bristol, BS10 5NB, UK.

Emily J Hotton (EJ)

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Women & Children's Directorate, North Bristol NHS Trust, Bristol, BS10 5NB, UK.

Erik Lenguerrand (E)

Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Julia Wade (J)

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

Cathy Winter (C)

Women & Children's Directorate, North Bristol NHS Trust, Bristol, BS10 5NB, UK.

Tim J Draycott (TJ)

Women & Children's Directorate, North Bristol NHS Trust, Bristol, BS10 5NB, UK.

Joanna F Crofts (JF)

Women & Children's Directorate, North Bristol NHS Trust, Bristol, BS10 5NB, UK. jocrofts@me.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH